L. Caetano M. Antunes, Julian E. Davies and B. Brett Finlay | Jan 1, 2011 | 10 min read
As much as rainforests or deep-sea vents, the human gut holds rich stores of microbial chemicals that should be mined for their pharmacological potential.
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Prior to a 2019 preprint, “glycoRNAs” weren’t known to exist. Now, the researchers who found them say they’re on lots of cells and may play a role in immune signaling.